Onelife Capital Advisors Ltd

AGM details

• Held via VC/OAVM at three o'clock in the afternoon.
• Remote e-voting facility provided to members prior to meeting.

Resolutions

• Adoption of audited financial statements and accompanying reports (ordinary).
• Director by rotation proposed for re-appointment (ordinary).
• Final dividend per share proposed (ordinary).

Voting results

• Outcome of resolutions not disclosed in the filing.

Onelife Capital Advisors Limited – Trading Window closed from 01 Oct 2026 until 48 hours after declaration of Un-Audited Financial Results for quarter ended 30 Sep 2026

Warrant conversion details

• Onelife converted 2,425,000 convertible warrants of Swojas Foods Limited into equity shares.
• 75% of warrant subscription amount paid, totaling ₹30,009,375, for the conversion.
• Swojas Foods Limited allotted 2,425,000 equity shares to Onelife on 24 September 2026.
• Equity shares allotted have a face value of ₹10 each.
• Onelife continues to hold 2,758,838 convertible warrants in Swojas Foods Limited.
• Board of Swojas Foods Limited approved the allotment on 24 September 2026.
• Transaction is in ordinary course under the Companies Act and SEBI Regulations.

Financials

• Standalone total income 679.61 Lakhs; PAT 208.16 Lakhs; EPS 1.35.
• Consolidated total income 3,051.55 Lakhs; PAT 550.50 Lakhs; EPS 3.58.
• Rights Issue of ₹36.00 Crores expanded equity base; 2.40 crore new shares issued.
• Record date for final dividend fixed at 22 September 2026.
• Paid-up equity capital post-rights ₹37.36 Crores.

Dividend corrigendum

• Corrigendum fixes final dividend disclosure to ₹0.01 per equity share (0.10%).
• Board approved final dividend on 30 May 2026; subject to AGM.
• Corrigendum and updated Annual Report uploaded on company website.
• Final dividend amount corrected to ₹3,73,600 for 37,360,000 shares.

Capital structure & capital allocation

• Debt-to-equity ratio reported at 0.10; current ratio 2.82; ROE 0.02; ROCE 0.02.
• Rights issue price ₹15 per share; premium ₹5; 2,40,00,000 shares issued.
• 75% of right issue proceeds deployed to Dealmoney Commodities; 25% unutilised as of 31 Mar 2026.
• Record date for dividend entitlement remains 22 Sep 2026.

Business & strategy

• Strategy anchored on technology, funding, and governance; Ready applications and Onelifetouch Super App.
• Five-core verticals focus on Advisory, Investment, Management, Technology, and a unified platform.
• AI and data science integrated for predictive diagnostics and analytics.

Governance & risk

• Board size seven; executive chair Prabhakara Naig; CEO Pandoo Naig appointed 1-Jun-2026.
• Audit: Rafik & Associates; Secretarial: Ajay Kumar & Co; no material audit qualification.
• Cyber security incident on 30-Jan-2026; data reconstructed; controls strengthened.
• SEBI order (Mar 2025) stayed; appeal before SAT ongoing.

Related party transactions & ESOS

• Related party transactions are arm's length and in ordinary course.
• ESOS 2026 approved; up to 18.68 lakh stock options; listing approvals pending.
• Eight subsidiaries monitored; strategic use of DCPL for margin money.

Subsidiaries & risk management

• Eight subsidiaries; key assets include Dealmoney Commodities, Dealmoney Real Estate, Eyelid Infrastructure.
• Management monitors risks via Risk Management and SEC POSH & ESG framework.
• IEPF: unclaimed dividends/shares handled per policy.

Outlook & growth

• Exploring subsequent corporate funding rounds to back scaling.
• Aim to activate other high-growth verticals; leverage advanced software, governance.

Book closure and AGM details

• Book closure: 23 September 2026 to 29 September 2026 (inclusive).
• Purpose: Annual General Meeting.
• Cut-off date: 22 September 2026 to determine voting eligibility.
• AGM date and time: 29 September 2026 at 3:00 PM (VC/OAVM).
• E-voting period: 26 September 2026 9:00 AM to 28 September 2026 5:00 PM.
• Security: Equity shares, face value ₹10 each.

AGM timing and voting

• 19th AGM scheduled for 29 September 2026 via VC/OAVM.
• Register of Members closed 23–29 September 2026.
• e-voting cut-off date set at 22 September 2026.
• e-voting window 26–28 September 2026.

Draft Notice and Annual Report

• Draft Notice and Annual Report for FY 2025-26 approved.

E-voting Scrutinizer

• M/s Mukesh Siroya and Co. appointed Scrutinizer for e-voting.

Director appointment

• Re-appointment of Mr. Pandoo Naig (DIN 00158221) effective 29 September 2026.

Director profile

• Profile: Director and CEO; extensive capital markets, real estate, software, healthcare experience.

Dividend record date

• Record date for final dividend fixed at 22 September 2026.
• Dividend subject to Members' approval at AGM.

Meeting Details

• Board meeting on 02 September 2026 to be held via video conferencing.

Key Agenda Items

• Fix AGM date, place, time and book closure; determine voting entitlement cut-off.
• Approve Draft Notice and Annual Report for FY 2025-2026.
• Appoint M/s. Mukesh Siroya and Co. as Scrutinizer for e-voting.
• Consider and fix Record Date for final dividend eligibility for FY 2025-26.
• Transact incidental and ancillary matters as may be decided by the board.

Issue Overview

• Right issue of equity shares.
• Total size: 36 Cr; net proceeds details not separately disclosed.
• Main objectives: fund margin money for the subsidiary and general corporate purposes.

Utilisation of Proceeds

• Utilisation aligned with disclosures; no deviations observed.
• Object 1: Margin money funding for Dealmoney Commodities Pvt Ltd; fully utilized.
• Object 2: General Corporate Purpose; fully utilized.
• Object 3: Issue Related Expenses; fully utilized.
• Total unutilised funds: nil.

GCP

• Total GCP allocation: 3.84 Cr.
• Business Advances: 1.50 Cr.
• Investment in Dealmoney Real Estate Private Limited: 1.50 Cr.
• Salary Disbursement: 0.48 Cr.
• Interest on loan: 0.17 Cr.
• Duties and Taxes: 0.13 Cr.
• Exchange Annual Fees: 0.06 Cr.
• Board approval evidenced by board minutes dated March 27, 2026.

Governance and Compliance

• Approvals: No government/statutory approvals required for objects.
• Material events: None observed affecting viability.
• Other information: No material information evident.